SOLV Stock Summary and Trading Ideas (Solventum | NYSE:SOLV)

In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.

Solventum trades on the NYSE stock market under the symbol SOLV.

As of January 16, 2026, SOLV stock price declined to $79.48 with 725,117 million shares trading.

SOLV has a beta of 0.86, meaning it tends to be less sensitive to market movements. SOLV has a correlation of 0.24 to the broad based SPY ETF.

SOLV has a market cap of $13.78 billion. This is considered a Large Cap stock.

Last quarter Solventum reported $2 billion in Revenue and $1.50 earnings per share. This beat revenue expectation by $29 million and exceeded earnings estimates by $.07.

The top ETF exchange traded funds that SOLV belongs to (by Net Assets): VTI, VOO, VB, VBR, RSP.

SOLV has underperformed the market in the last year with a price return of +9.3% while the SPY ETF gained +18.1%. However, in the short term, SOLV had mixed performance relative to the market. It has outperformed in the last 3 months, returning +11.3% vs +5.0% return in SPY. But in the last 2 weeks, SOLV shares have been beat by the market, returning +0.6% compared to an SPY return of +1.2%.

SOLV support price is $79.20 and resistance is $81.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SOLV shares will trade within this expected range on the day.